Last reviewed · How we verify
Pacritinib and Rifampin
Pacritinib and Rifampin is a Small molecule drug developed by CTI BioPharma. It is currently in Phase 1 development. Also known as: PAC400 mg and rifampin 600mg.
At a glance
| Generic name | Pacritinib and Rifampin |
|---|---|
| Also known as | PAC400 mg and rifampin 600mg |
| Sponsor | CTI BioPharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pacritinib and Rifampin CI brief — competitive landscape report
- Pacritinib and Rifampin updates RSS · CI watch RSS
- CTI BioPharma portfolio CI
Frequently asked questions about Pacritinib and Rifampin
What is Pacritinib and Rifampin?
Pacritinib and Rifampin is a Small molecule drug developed by CTI BioPharma.
Who makes Pacritinib and Rifampin?
Pacritinib and Rifampin is developed by CTI BioPharma (see full CTI BioPharma pipeline at /company/cti-biopharma).
Is Pacritinib and Rifampin also known as anything else?
Pacritinib and Rifampin is also known as PAC400 mg and rifampin 600mg.
What development phase is Pacritinib and Rifampin in?
Pacritinib and Rifampin is in Phase 1.
Related
- Manufacturer: CTI BioPharma — full pipeline
- Also known as: PAC400 mg and rifampin 600mg
- Compare: Pacritinib and Rifampin vs similar drugs
- Pricing: Pacritinib and Rifampin cost, discount & access